After the GEMINI-ACS-1 trial


YILMAZ M. B.

TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, vol.45, pp.8-9, 2017 (ESCI) identifier identifier identifier

Abstract

The GEMINI-ACS-1 trial has recently been published. It was designed to test whether low dose rivaroxaban as an antithrombotic agent is as safe as aspirin in patients with acute coronary syndromes (ACS). The trial is important to set light to future of ACS management.